NASDAQ
0.29USD
-0.04 (-11.98%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
936.3K
P/E
—
EPS
—
Beta
1.83
52W range
0.251-5.6
Day range
0.29–0.34
Open
0.33
Prev close
0.33
Volume
316.6K
Avg volume
503.2K
Dividend
0.00
IPO
2021-11-11
https://www.prnewswire.com/news-releases/ukraine-ministry-of-health-accepts-entolimod-dossier-for-formal-review-under-regulatory-equivalence-pathway-302832086.html · 7/22/2026+0.80
https://www.prnewswire.com/news-releases/valion-bio-advances-integrated-biodefense-and-immunology-platform-through-continued-government-engagement-domestic-manufacturing-and-oncology-expansion-302824523.html · 7/14/2026+0.80
https://www.prnewswire.com/news-releases/afrriniaid-designs-proprietary-pbi-bm2-5-protocol-to-evaluate-valion-bios-nasdaq-vbio-entolimod-as-the-first-and-only-treatment-for-gi-ars-302810088.html · 6/25/2026+1.00
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
